Početna stranicaBSLN • SWX
add
Basilea Pharmaceutica AG Allschwil
Preth. zaklj. cijena
41,15 CHF
Dnevni raspon
40,60 CHF - 41,45 CHF
Godišnji raspon
32,00 CHF - 49,00 CHF
Tržišna kapitalizacija
540,62 mil. CHF
Prosječna količina
17,18 tis.
P/E omjer
47,10
Prinos dividende
-
Glavno tržište vrijednosnica
SWX
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (CHF) | pro 2023.info | Godišnja promjena |
|---|---|---|
Prihod | 36,36 mil. | −19,30 % |
Operativni troškovi | 7,96 mil. | 12,34 % |
Neto dohodak | −10,69 mil. | −187,82 % |
Neto profitabilnost | −29,41 | −208,81 % |
Zarada po dionici | — | — |
EBITDA | −7,88 mil. | −152,08 % |
Efektivna porezna stopa | 0,08 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (CHF) | pro 2023.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 59,93 mil. | −29,21 % |
Ukupna imovina | 173,29 mil. | −21,53 % |
Ukupne obveze | 183,29 mil. | −24,12 % |
Ukupni kapital | −10,00 mil. | — |
Dionice u optjecaju | 12,00 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | −49,58 | — |
Povrat imovine | −11,81 % | — |
Povrat kapitala | −17,26 % | — |
Tok novca
Neto promjena novca
| (CHF) | pro 2023.info | Godišnja promjena |
|---|---|---|
Neto dohodak | −10,69 mil. | −187,82 % |
Gotovina od poslovanja | −3,81 mil. | −210,31 % |
Gotovina iz ulaganja | −322,50 tis. | −100,69 % |
Gotovina iz financiranja | −20,11 mil. | −4,52 % |
Neto promjena novca | −24,31 mil. | −178,80 % |
Slobodan tok novca | −4,62 mil. | −154,24 % |
Više
Basilea Pharmaceutica is a multinational specialty biopharmaceutical company headquartered in Basel, Switzerland. It was formed as a spin-off entity from the drug giant Hoffmann–La Roche in October 2000. It is engaged in the development of antibiotics, antifungals and oncology drugs for treatment of invasive aspergillosis and mucormycosis. Basilea is publicly traded on the SIX Swiss exchange.
The company is based in Basel, Switzerland. It has subsidiaries in France, Germany, Denmark, the People's Republic of China, Spain, the United Kingdom, and the United States of America. According to stock filings, it had 196 employees as of June 2007.
Among the company's notable products is Isavuconazole, an intravenous and oral antifungal, which received orphan drug status designation by the United States Food and Drug Administration in 2013. The company also manufactures pharmaceuticals for use against methicillin-resistant Staphylococcus aureus. Wikipedia
Glavni izvršni direktor
Osnovano
lis 2000
Web-lokacija
Zaposlenici
147
